Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review
British Journal of Haematology · 2024-02 · 204 (2) · 638-643
DOI: 10.1111/bjh.19035 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Haematology, online erschienen am 12.08.2023. Verfasst von Nicholas C J Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Bortezomib, Purpura, Thrombotic Thrombocytopenic, Recurrence. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Society of Hematology HONORS Award, National Med-Peds Residents Association Research Grant.
Abstract (Originalsprache)
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life‐threatening haematological condition. Initial treatment involves plasma exchange (PLEX), corticosteroids, caplacizumab and rituximab. In relapsed and refractory cases despite initial treatments, further immune‐modulating therapy includes the proteasome inhibitor, bortezomib. Evidence for bortezomib in this setting is limited to case reports and case series. We report our experience and perform a systematic review of the literature. We identified 21 publications with 28 unique patients in addition to our cohort of eight patients treated with bortezomib. The median age of patients was 44 years (IQR: 27–53) and 69% female. They were usually in an initial, refractory presentation of iTTP where they had received PLEX, corticosteroids, rituximab and another line of therapy. After bortezomib administration, 72% of patients had a complete response, with 85% maintaining a durable response without relapse at the last follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
- Department of Pediatrics, University of Texas Southwestern, Dallas, Texas, USA.
- Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern, Dallas, Texas, USA.
- Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
ORCID-Profile: Nicholas C J Lee, Sean Yates, Natalie R Bavli
Förderung
- American Society of Hematology HONORS Award
- National Med-Peds Residents Association Research Grant
Zitieren
APA
Lee, N. C. J., Yates, S., Rambally, S., Sarode, R., Ibrahim, I. F., Shen, Y. M., Hofmann, S. L., & Bavli, N. R. (2024). Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review. British Journal of Haematology, 204(2), 638-643. https://doi.org/10.1111/bjh.19035
Vancouver
Lee NCJ, Yates S, Rambally S, Sarode R, Ibrahim IF, Shen YM, et al. Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review. British Journal of Haematology. 2024;204(2):638-643. doi:10.1111/bjh.19035
BibTeX
@article{Lee2024,
author = {Lee, Nicholas C J and Yates, Sean and Rambally, Siayareh and Sarode, Ravi and Ibrahim, Ibrahim F and Shen, Yu-Min and Hofmann, Sandra L and Bavli, Natalie R},
title = {Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review},
journal = {British Journal of Haematology},
year = {2024},
volume = {204},
number = {2},
pages = {638--643},
doi = {10.1111/bjh.19035}
}
EUVIMED